BMJ Open  Protocol for a MULTI-centre feasibility study to assess the use of $^{99m}$Tc-sestamibi SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Hannah Warren 1,2, Thomas Wagner,3 Michael A Gorin,4 Steven Rowe,5,6 Beverley Fiona Holman,3 Deborah Pencharz,3 Soha El-Sheikh,2,7 Ravi Barod,1,2 Prasad Patki,2 Faiz Mumtaz,1,2 Axel Bex,1,2 Veeru Kasivisvanathan 1, Caroline M Moore 1,8 Nicholas Campain,9 Jon Cartledge,10 Andrew Scarsbrook,11 Fahim Hassan,12 Tim S O’Brien,13 Grant D Stewart 1,14 Iosif Mendichovszky,15,16 Sabina Dizdarevic,17,18 Ammar Alanbuki,19 William H Wildgoose,20 Tze Wah,11 Cecilia Vindrola-Padros 1,21 Elena Pizzo,22 Hakim-Moulay Dehbi,23 Paula Lorgelly,22 Kunirchi Gurusamy 1,24 Mark Emberton 1,8 Maxine G B Tran1,2


Received 16 August 2022
Accepted 30 December 2022

ABSTRACT

Introduction The incidence of renal tumours is increasing and anatomic imaging cannot reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours are benign, with oncocytomas the most common type. Biopsy has not been routinely adopted in many centres due to concerns surrounding non-diagnostic rate, bleeding and tumour seeding. As a result, benign masses are often unnecessarily surgically resected. $^{99m}$Tc-sestamibi SPECT/CT has shown high diagnostic accuracy for benign renal oncocytomas and other oncocyctic renal neoplasms of low malignant potential in single-centre studies. The primary aim of MULTI-MIBI is to assess feasibility of a multicentre study of $^{99m}$Tc-sestamibi SPECT/CT against a reference standard of histopathology from surgical resection or biopsy. Secondary aims of the study include obtaining estimates of $^{99m}$Tc-sestamibi SPECT/CT sensitivity and specificity and to inform the design and conduct of a future definitive trial.

Methods and analysis A feasibility prospective multicentre study of participants with indeterminate, clinical T1 renal tumours to undergo $^{99m}$Tc-sestamibi SPECT/CT (index test) compared with histopathology from biopsy or surgical resection (reference test). Interpretation of the index and reference tests will be blinded to the results of the other. Recruitment rate as well as estimates of sensitivity, specificity, positive and negative predictive value will be reported. Semistructured interviews with patients and clinicians will provide qualitative data to inform onward trial design and delivery. Training materials for $^{99m}$Tc-sestamibi SPECT/CT interpretation will be developed, assessed and optimised. Early health economic modelling using a decision analytic approach for different diagnostic strategies will be performed to understand the potential cost-effectiveness of $^{99m}$Tc-sestamibi SPECT/CT.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ MULTI-MIBI is the first multicentre prospective study to assess $^{99m}$Tc-sestamibi SPECT/CT in the evaluation of indeterminate renal tumours.
⇒ A composite reference standard of biopsy or surgical pathology allows generalisability of results to patients unwilling or unable to undergo surgical resection.
⇒ Blinding of clinicians interpreting index and reference tests reduces risk of bias.
⇒ Possible study limitations include the risk of non-diagnostic renal tumour biopsies and tumour misclassification on biopsy.
⇒ If the primary outcome (successful recruitment) is met, this will inform a large-scale multicentre study.

21/6/2022. Study outputs will be presented and published nationally and internationally.

Trial registration number ISRCTN12572202.

INTRODUCTION

The widespread use of cross-sectional imaging has led to an increase in the incidental detection of renal tumours. Based on data from surgical series, it is estimated that up to 30% of renal tumours are benign, with an increasing prevalence of benign histology with decreasing tumour size. The most common type of benign tumour is the oncocytoma. Unlike renal cell carcinoma (RCC), which commonly requires treatment, renal oncocytomas can be safely managed expectantly. However, a critical challenge lies in the identification of benign renal...
tumours, as traditional anatomic imaging techniques such as ultrasound, CT and MRI are unable to reliably distinguish between the various renal tumour histologies. Although renal mass biopsy can help in this regards, the relatively high non-diagnostic rate (~15%) and associated risk of complications with this procedure have led to its limited adoption in clinical practice. Thus, the majority of patients presenting with an incidental renal mass undergo treatment for a presumed cancer, exposing those with benign tumours to unnecessary surgical risk while consuming significant health resources.

Investigation of new imaging approaches to improve characterisation of incidentally detected small renal masses has been identified as a priority research need by the Renal Cancer Gap Analysis Collaborative, a group composed of clinicians, researchers, patients and caregivers. In recent years, 99mTc-sestamibi SPECT/CT has emerged as a promising non-invasive tool for the identification of benign renal oncocytomas. 99mTc-sestamibi is a lipophilic cationic radiopharmaceutical that readily accumulates in cells with high concentrations of mitochondria, such as renal oncocytomas. Conversely, most histologic subtypes of RCC are relatively devoid of mitochondria and express membrane multidrug resistance pumps, which are known to actively export 99mTc-sestamibi out of cells. These biological differences result in oncocytomas appearing avid, or ‘hot’ and RCCs non-avid or ‘cold’ on MIBI-kidney studies. A systematic review and meta-analysis including 117 renal lesions from single-centre studies showed pooled specificity of MIBI-kidney to detect renal oncocytomas versus other renal lesions was 92% (95% CI 72% to 98%) and 88% (95% CI 79% to 94%), respectively. No previous trials of MIBI-kidney have been conducted in the United Kingdom (UK), and there have been no multicentre trials.

One potential limitation of 99mTc-sestamibi SPECT/CT imaging of renal tumours is that a subset of RCCs exhibits relatively high intracellular concentrations of mitochondria and, therefore, display uptake of the radiotracer. These tumours include the chromophobe subtype of RCC and other oncocytic/chromophobe RCC. It is reassuring to note that these tumours exhibit generally indolent behaviour and low metastatic potential with excellent outcomes on active surveillance. We, therefore, termed this group of tumours as oncocytic renal neoplasms of low malignant potential, there is interest in utilising this test within the UK National Health System (NHS). However, the literature on 99mTc-sestamibi SPECT/CT remains limited to single centres reporting relatively few tumours. We have recently reported on a pump-priming pilot study in the UK. Herein, we present the protocol for our feasibility study with the following aims: to evaluate the feasibility of a large scale, UK-based, multicentre, clinical trial of 99mTc-sestamibi SPECT/CT in the diagnostic pathway for renal tumours and to obtain estimates of sensitivity and specificity with which to power a larger scale trial.

METHODS AND ANALYSIS

Study methods are reported with reference to Standard Protocol Items: Recommendations for Interventional Trials Checklist (SPIRIT) and SPIRIT-Path extension for cellular and molecular pathology content in clinical trial protocols.

Study design

A prospective, multicentre study to assess the feasibility and diagnostic performance characteristics of 99mTc-sestamibi SPECT/CT in adults (n=50) with solid, enhancing clinical renal tumours (2–7 cm) on cross-sectional imaging. The study design is summarised in figure 1.

Objectives and outcomes

The primary aim of the study is to evaluate whether a multicentre diagnostic test evaluation study of 99mTc-sestamibi SPECT/CT can recruit successfully. Secondary aims are to assess patient and clinician acceptability, refine inclusion/exclusion criteria, sample size requirements and determine clinician training needs for 99mTc-sestamibi SPECT/CT interpretation.

The study objectives are to determine:

► Will patients consent to have a 99mTc-sestamibi SPECT/CT prior to surgery or biopsy, including those from under-represented and underserved groups?

► What factors influence patient’s decisions to participate?

► What are the perceptions of clinicians and patients of 99mTc-sestamibi SPECT/CT?

► What barriers and facilitators are there for adoption of 99mTc-sestamibi SPECT/CT?

► What is the potential cost-effectiveness of using 99mTc-sestamibi SPECT/CT within the NHS?

► What are the minimally acceptable criteria (MAC) for the sensitivity and specificity of 99mTc-sestamibi SPECT/CT?

► Is it feasible to train nuclear medicine clinicians across the UK, including those serving under-represented and underserved communities, to interpret 99mTc-sestamibi SPECT/CT?

The study outcomes are as follows:

Primary outcome

► Recruitment rate.

Secondary outcomes

► Sensitivity and specificity of MIBI to detect benign lesions in this study.
Screening for eligibility

**Inclusion Criteria**
- ≥18 years
- Solid CT1 renal tumour ≥2cm on CT/MRI
- Undergoing surgical resection or biopsy as standard of care

**Exclusion Criteria**
- Cystic tumour
- Pregnant or breastfeeding
- Known allergy to 99mTc-Sestamibi
- Unwilling or unable to undergo study procedures

---

**Study setting**
The study will be conducted in 3–6 NHS hospitals in England.

**Eligibility criteria**
Consecutive patients discussed at specialist multidisciplinary team meetings will be screened for eligibility over a planned 15-month recruitment period. The inclusion criteria for entry to the study are adult patients (≥18 years) of any gender with a clinical T1 indeterminate solid renal tumour (2–7 cm) on cross-sectional imaging, willing and able to provide informed consent. Patients will be required to have surgery or renal tumour biopsy planned as part of their standard clinical care. Patients entering watchful waiting or active surveillance pathways without histologic diagnosis will be excluded. Other exclusion criteria will include cystic tumours, pregnant and breastfeeding patients, those with a known allergy to 99mTc-Sestamibi and those unwilling or unable to undergo the study procedures.

**Test methods**

**Index test**
Nuclear medicine clinicians involved in the study will receive study-specific training on the interpretation of 99mTc-Sestamibi SPECT/CT from international experts at the beginning of the recruitment period. The training will include a lecture on 99mTc-Sestamibi SPECT/CT principles, ‘hands-on training’ supported by experienced faculty and a precourse and postcourse assessment.

900 MBq of 99mTc-Sestamibi will be injected intravenously in a single bolus, 75 min before SPECT/CT acquisition of the abdomen with the superior extent of the field-of-view set to the top of the liver dome. CT and SPECT image acquisition will follow manufacturer instructions and local experience. At minimum, we suggest that participating centres have SPECT/CT systems with the following specifications: at least two-slice helical diagnostic CT scanner, available low-energy all-purpose or low-energy high-resolution collimator, gamma camera or digital detector elements appropriate for 140-kEV photopeak acquisition and manufacturer-derived iterative reconstruction that includes scatter and attenuation correction.

The reporting clinician will document a qualitative assessment of the tumour as avid, non-avid or indeterminate on reconstructed SPECT/CT images, blinded to clinical information and the result of the histopathology reference test. A spherical region of interest will be drawn to measure maximum uptake in attenuation-corrected images within (a) the tumour and (b) the ipsilateral renal parenchyma. A ratio of maximum uptake between the tumour and normal renal parenchyma will be calculated. All 99mTc-Sestamibi SPECT/CT scans will be transferred for central review at the lead site (Royal Free Hospital) and discordant reports resolved by discussion and consensus. Local site clinicians will report a subset of studies a second time at the end of the recruitment period to allow assessment of intrarater reliability.
Reference test

Histopathology from the final surgical resection specimen is considered the ‘gold standard’ diagnostic test to determine renal tumour subtype. It is worth noting that although biopsy allows for histological diagnosis, questions remain about the accuracy of this technique for determining the precise histology of a renal tumour, mostly relating to an approximately 15% non-diagnostic rate of this procedure and the need for architectural findings in the tissue sample to definitively diagnose some tumour types. Despite this, we feel a composite findings in the tissue sample to definitively diagnose some tumour types. 

Pathologists will be blinded to the 99mTc-SESTAMIBI SPECT/CT result. Pathology slides/images will be exported for central review by a specialist uro-oncology pathologist and archiving at the lead site (Royal Free Hospital).

Sample size and recruitment

The aim of this study is to assess the feasibility of a multicentre study of 99mTc-SESTAMIBI SPECT/CT in the diagnostic pathway for renal tumours. Data from the feasibility phase will be used to inform the design and sample size of the definitive trial. We will aim to recruit 50 patients from 3–6 centres. This sample size will allow us to assess if 80% (95% CI 70% to 90%) of approached patients agree to undergo the study scan. Additionally, this sample size will have sufficient power to detect if there is a significant difference in the estimates of sensitivity between our study population and those reported in the literature. A sample size of 40 patients would achieve 81% power to detect a sensitivity of 0.65 (representing an estimate outside the lower end of the 95% CI for sensitivity from the literature) using a two-sided binomial test at the 5% two-sided alpha level. A 20% inflation to 50 patients, will allow for possible dropouts and other methodological challenges.

Analysis

Qualitative study of feasibility and acceptability

Qualitative data obtained from semistructured interviews (conducted either by telephone or on virtual platforms for example, Microsoft Teams) with patients, carers and staff will be combined with documentary analysis (reports, meeting minutes) and will be used to inform within trial decision-making processes via a rapid feedback evaluation approach.

Transcripts and key documents will be imported into NVivo and analysed using framework analysis. Data collection and analysis will be carried out in parallel and emerging findings will be shared with the trial team on a monthly basis to inform trial design and delivery.

The findings from the interviews and documentary analysis will be used to develop a discrete choice experiment to gain an understanding of preferences for trial participation and how participants trade-off different attributes of 99mTc-SESTAMIBI SPECT/CT with other management scenarios. In addition, a survey will be conducted—informed by a rapid review of survey instruments reported in the published literature—to capture the acceptability of interventions in clinical trials, to provide insights into the barriers or facilitators to patient decision-making and determine the degree of acceptability of 99mTc-SESTAMIBI SPECT/CT.

Study of diagnostic accuracy

Diagnostic accuracy of 99mTc-SESTAMIBI SPECT/CT will be estimated by generating 2×2 tables for both avid and non-avid qualitative assessment, and relative radiotracer uptake ratio >0.6 and ≤0.6 for external validation of a predefined threshold from the literature. Analysis of a range of relative uptake ratios will be explored to assess performance at different thresholds. Diagnostic accuracy of 99mTc-SESTAMIBI SPECT/CT will be calculated in terms of sensitivity, specificity and predictive values along with their 95% CIs. The prevalence of renal oncocytoma and other histology subtypes will be calculated with a 95% CI.

Inconclusive test results will be reported. The proportion of participants with invalid 99mTc-SESTAMIBI SPECT/CT results, for example, due to technical failure, will be reported. The proportion of valid but inconclusive results will also be reported, and their impact on estimates will be assessed by including them as either test positive or test negative in sensitivity analyses. This is to inform how 99mTc-SESTAMIBI SPECT/CT might be used in the diagnostic pathway. If intended as a replacement test for histopathology, a valid but indeterminate 99mTc-SESTAMIBI SPECT/CT would be considered non-avid to avoid misclassifying malignant tumours as benign. If, however, 99mTc-SESTAMIBI SPECT/CT were to be used as a triage test, where avid tumours undergo confirmatory biopsy, then an indeterminate test could be considered avid to reduce the risk of surgery for benign pathology. The proportion of patients who do not complete the study schedule defined in the protocol will be calculated.

We will assess inter-rater and intrarater agreement using percentage agreement and Gwet’s first-order agreement coefficient.

We do not anticipate the need to adjust for diagnostic drift for the reference test, given the short study duration. However, if current pathologic guidelines for renal neoplasia are updated during the course of the study archived samples will be rereviewed and reported according to the latest guidelines.

Study of health economics

Health economic modelling will be used to understand the potential cost-effectiveness of 99mTc-SESTAMIBI SPECT/CT in the evaluation of patients presenting...
with an indeterminate renal mass. A decision analytic approach will compare the following scenarios:

1. Patients have empiric surgery (current standard-of-care).
2. Patients undergo tumour biopsy, those consistent with cancer have surgery and those with benign histology have active surveillance.
3. Patients undergo 99mTc-sestamibi SPECT/CT, those with a ‘cold’ scan (suggestive of cancer) have surgery and those with a ‘hot’ scan (suggestive of benign tumour) have active surveillance.
4. Patients undergo 99mTc-sestamibi SPECT/CT, those with a ‘cold’ scan have surgery, and those with a ‘hot’ scan have a confirmatory biopsy (MIBI would be likened to a triage test to select patients for biopsy for tissue confirmation before embarking on active surveillance).

The model will be populated with evidence from trial and published literature. Where data are not available, an expert elicitation approach will be employed to provide parameter values. The analysis will then compare the different approaches to standard-of-care by estimating the incremental cost-effectiveness ratios and assessing the uncertainty of these estimates using value of information (VOI) analysis. The VOI analysis will quantify the potential value of further research, identify areas of study with the greatest potential benefit and generate recommendations on future study designs.

**Data collection**

Case report forms (CRFs) in paper and electronic format will be trialled. The CRFs will not bear the participant’s name or other directly identifiable data. The participants’ study ID will be used for identification purposes. Study-related procedures will be carried out during the baseline routine clinical visit, 99mTc-sestamibi SPECT/CT visit and thereafter by telephone or email according to participant preference, as shown in table 1. CCRFs will be checked for completeness and accuracy by designated individuals against source data. Study data captured in paper format will be transcribed to an electronic database. Quality of life data will be captured using the previously validated EQ-5D-5L instrument. No analysis will begin until accuracy of the data has been assured. The final trial data set will be accessible to the chief investigator, statistician and health economist.

A participant may withdraw their consent to participate at any time prior to the 99mTc-sestamibi SPECT/CT scan. The decision to withdraw will be recorded in the CRF and medical notes. Participants withdrawing prior to 99mTc-sestamibi SPECT/CT will be replaced. If following 99mTc-sestamibi SPECT/CT, the participant states they do not wish to participate in scheduled follow-up (EQ-5D-5L completion), or deviate from the protocol, then data already collected will be kept and analysed. These patients will not be replaced.

Baseline data items will include the following:

- Baseline demographics (age, gender, ethnicity, medical and surgical history, current medication and allergies).
- Baseline blood test results (full blood count, renal function, coagulation screen).
- Baseline imaging (multiphase (to include non-contrast, arterial-phase, venous-phase and delayed-phase), contrast-enhanced CT or MRI of the abdomen).
- Renal tumour characteristics (complexity scoring, location, number of lesions).
- Quality of life questionnaire (EQ-5D-5L).
- Adverse events (AEs) during and immediately post-MIBI-kidney.

The following data will be collected at postintervention follow-up by telephone or email:

<table>
<thead>
<tr>
<th>Procedures</th>
<th>Screening</th>
<th>Baseline</th>
<th>Intervention</th>
<th>24–72 hour follow-up</th>
<th>Follow-up (standard of care)</th>
<th>Interview follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consent (obtained by clinician/ research nurse)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99mTc-sestamibi SPECT/CT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QoL questionnaire</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse event reporting</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histology test and result</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Semi-structured interview</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


---

Table 1 Visit schedule and assessments

---

AEs following MIBI-kidney.

Quality of life questionnaire (EQ-5D-5L).

After participation in the trial participants will continue follow-up as per standard care.

Patient and public involvement

Patient and public involvement (PPI) has been central to the project concept and design. A pre-study PPI focus group informed the trial protocol and plain English summary. An online PPI survey received 231 responses and indicated 90% would be willing to participate in the proposed study. In addition to the qualitative workstream, PPI representatives from Kidney Cancer UK will form a study support group, meeting at regular intervals throughout the trial to provide advice and input on any trial challenges and developing/approving dissemination materials.

Harms

99mTc-Sestamibi has been used for cardiac and parathyroid imaging globally for decades and is known to be a safe radiopharmaceutical. The radiation exposure from one MIBI-kidney scan is 14 mSv, equivalent to approximately 5 years of average UK background radiation. As MIBI-kidney is the only study intervention in addition to standard care, a data-monitoring committee will not be required.

All AEs, whether related or unrelated to MIBI-kidney, will be documented in the patient’s notes, study CRF and the AE log. The AE log will be sent to the Sponsor (University College London & University College London Hospitals Joint Research Office) at least once per year. Incidental clinically significant abnormalities identified on MIBI-kidney will be recorded as AEs and communicated to the referring clinician and patient. All serious AEs will be recorded on an SAE form and reported to the Sponsor and relevant REC within 15 working days of the chief investigator becoming aware of the event.

Auditing

Investigators and sites will permit trial-related monitoring, audit, REC review and regulatory inspection(s) and provide access to required data and documents.

Ethics and dissemination

Ethical approval for this study has been granted (UK HRA REC 20/YH/0279). Protocol amendments will be promptly disseminated to Sponsor, investigators and trial steering committee members. The study is recorded on the trial registration website. The trial involves the administration of unsealed radioactive substances. An Administration of Radioactive Substances Advisory Committee certificate has been granted (AA-3990).

Study outputs will be presented at national and international conferences and published in peer-reviewed journals. Patient representatives will be involved in output dissemination to the public individual trial participants via study newsletter.

Author affiliations

1Division of Surgery and Interventional Science, University College London, London, UK
2Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK
3Department of Nuclear Medicine, Royal Free Hospital, London, UK
4Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
5Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
7Department of Pathology, Royal Free Hospital, London, UK
8Department of Urology, University College Hospital, London, UK
9Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
10Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
11Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
12Department of Nuclear Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
13Department of Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
14Department of Surgery, University of Cambridge, Cambridge, UK
15Department of Radiology, University of Cambridge, Cambridge, UK
16Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
17Department of Nuclear Medicine, University Hospitals Sussex NHS Foundation Trust, Worthing, UK
18Brighton and Sussex Medical School, Brighton, UK
19Department of Urology, University Hospitals Sussex NHS Foundation Trust, Worthing, UK
20Patient Representative, London, UK
21Rapid Research, Evaluation and Appraisal Lab (RREAL), Department of Targeted Intervention, University College London, London, UK
22Department of Applied Health Research, University College London, London, UK
23Institute of Clinical Trials and Methodology, University College London, London, UK

Twitter

Hannah Warren @hanhahwarren, Veeru Kasiviswanathan @veerukasi, Caroline M Moore @mrsprostate, Andrew Scarsbrook @andyscarbsbrook, Ammar Alabnuki @AmmarAlabnuki, Tze Wah @TzeWah1 and Cecilia Vindrola-Padros @CeciliaVindrola

Acknowledgements

We are grateful for the invaluable contribution provided by patient representatives.HW is funded by The Urology Foundation and Pan London Cancer Alliance (Royal Marsden Partners, North Central London Cancer Alliance, North East London Cancer Alliance, South East London Cancer Alliance and the NIHR BRCs). VK receives funding from Prostate Cancer UK and the John Black Charitable Foundation. GDS and IAM are supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and GDS by the Cancer Research UK Cambridge Centre [C36855/A25177]. EP is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) North Thames at Bart’s Health NHS Trust. Mark Emberton receives research support from the United Kingdom’s National Institute of Health Research (NIHR) UCLH / UCL Biomedical Research Centre. He was conferred NIHR Senior Investigator Status in 2015. MBGT receives research funding from NIHR, St Peter’s Trust, Royal Free Charity, RCS, Facing up 2 Kidney Cancer and Kidney Cancer UK. The views expressed are those of the authors and not necessarily those of the funders.

Contributors

MGBT conceived the study and is the chief investigator and grant holder. HW and MGBT drafted the study protocol. HW, TW, MAG, SR, BFH, DP, SE-S, RB, PP, FM, AB, VK, CMW, NC, JC, AS, FH, TSOB, GDS, IM, SD, AA, WW, TMW, CV-P, EP, HM-D, PL, KS, ME and MGBT have contributed to study design, protocol writing and design of trial documents. SE-S was responsible for pathology content of the trial protocol. The Sponsor assisted with protocol writing and design of trial documents. The funding source was not involved in the trial design, protocol writing or design of trial documents and will not participate in its execution, analysis or interpretation. HW and MGBT drafted the manuscript and all other authors contributed to and approved the final document. Publications will be subject to the permission of the Sponsor. Responsibility to report on trial results will lie solely with the authors.
REFERENCES


